CA2648323A1 - Substituted ring fused azines and their use in cancer therapy - Google Patents

Substituted ring fused azines and their use in cancer therapy Download PDF

Info

Publication number
CA2648323A1
CA2648323A1 CA002648323A CA2648323A CA2648323A1 CA 2648323 A1 CA2648323 A1 CA 2648323A1 CA 002648323 A CA002648323 A CA 002648323A CA 2648323 A CA2648323 A CA 2648323A CA 2648323 A1 CA2648323 A1 CA 2648323A1
Authority
CA
Canada
Prior art keywords
benzofuran
dimethyl
quinazolinyl
propanediamine
dihydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002648323A
Other languages
English (en)
French (fr)
Inventor
William Alexander Denny
Bruce Charles Baguley
Elaine Shirley Marshall
Hamish Scott Sutherland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2648323A1 publication Critical patent/CA2648323A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002648323A 2006-04-07 2007-04-04 Substituted ring fused azines and their use in cancer therapy Abandoned CA2648323A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ546477 2006-04-07
NZ546477A NZ546477A (en) 2006-04-07 2006-04-07 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy
PCT/NZ2007/000077 WO2007117161A1 (en) 2006-04-07 2007-04-04 Substituted ring fused azines and their use in cancer therapy

Publications (1)

Publication Number Publication Date
CA2648323A1 true CA2648323A1 (en) 2007-10-18

Family

ID=38581368

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002648323A Abandoned CA2648323A1 (en) 2006-04-07 2007-04-04 Substituted ring fused azines and their use in cancer therapy

Country Status (8)

Country Link
US (1) US20090318479A1 (enExample)
EP (1) EP2004637A4 (enExample)
JP (1) JP2009533338A (enExample)
CN (1) CN101460490A (enExample)
AU (1) AU2007235751A1 (enExample)
CA (1) CA2648323A1 (enExample)
NZ (1) NZ546477A (enExample)
WO (1) WO2007117161A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046207A1 (en) * 2010-10-08 2012-04-12 Paraco Technology Limited Anti-parasitic substituted ring fused azine compounds
US8710064B2 (en) * 2011-10-20 2014-04-29 China Medical University 2-aryl-4-quinazolinones and their pharmaceutical compositions
BR112014030416A2 (pt) 2012-06-07 2017-06-27 Hoffmann La Roche composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção.
CA2874546A1 (en) 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
JP2016516691A (ja) 2013-03-11 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カリウムイオンチャネル阻害剤としてのイソキノリン
AU2014353006B2 (en) 2013-11-20 2019-04-04 Signalchem Life Sciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
CN107001358A (zh) * 2014-10-29 2017-08-01 东亚St株式会社 调节组蛋白赖氨酸脱甲基酶(kdm)催化活性的新型吡啶并嘧啶酮化合物
US20170057955A1 (en) * 2015-08-26 2017-03-02 Dong-A Socio Holdings Co., Ltd. Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs)
CN107721982B (zh) * 2017-10-16 2019-12-03 中山大学 一种抗肥胖症化合物及其制备方法和应用
CN110483394A (zh) * 2019-09-02 2019-11-22 广东工业大学 一种化合物的应用
CN113072543B (zh) * 2020-01-03 2022-07-22 南方医科大学 一种2-芳杂环基喹唑啉酮类化合物及其制备方法和用途
US20230339866A1 (en) * 2020-02-04 2023-10-26 TroBio Therapeutics Pty Ltd Quinazoline compounds and the use thereof in the treatment of cancer
AU2021342568B2 (en) 2020-09-21 2025-04-03 Landos Biopharma, Inc. Nlrx1 ligands
CN114044769B (zh) * 2021-11-25 2023-12-12 中山大学 一种β-吲哚喹唑啉酮衍生物及其制备方法和应用
CN117247374B (zh) * 2022-06-10 2026-03-17 四川科伦博泰生物医药股份有限公司 一种bcl-xl抑制剂及其制药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897432A (en) * 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
WO2000032175A2 (en) * 1998-12-02 2000-06-08 Pfizer Products Inc. METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
EP1088818B1 (en) * 1999-10-01 2004-11-03 F. Hoffmann-La Roche Ag Quinolin-4-yl derivatives
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
WO2002062767A1 (en) * 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Novel quinazoline derivatives

Also Published As

Publication number Publication date
EP2004637A1 (en) 2008-12-24
AU2007235751A1 (en) 2007-10-18
NZ546477A (en) 2009-04-30
EP2004637A4 (en) 2010-11-03
CN101460490A (zh) 2009-06-17
JP2009533338A (ja) 2009-09-17
US20090318479A1 (en) 2009-12-24
WO2007117161A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
US20090318479A1 (en) Substituted ring fused azines and their use in cancer therapy
US12129236B2 (en) PARG inhibitory compounds
CN103242341B (zh) 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
US10717711B2 (en) Amino quinazolines as kinase inhibitors
CN117069700B (zh) Egfr抑制剂及其制备和应用
AU2010214095B2 (en) Novel amino azaheterocyclic carboxamides
WO2009084695A1 (ja) ２－アミノキナゾリン誘導体
JP2006501201A (ja) 化合物、組成物および方法
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
He et al. New quinazoline derivatives for telomeric G-quadruplex DNA: Effects of an added phenyl group on quadruplex binding ability
TWI387601B (zh) 方法及中間物
WO2012131501A1 (en) Substituted benzimidazole compounds as cot kinase inhibitors
WO2021115432A1 (zh) 新型含喹唑啉类化合物及其中间体与应用
ITMI20082336A1 (it) Composti inibitori irreversibili di egfr con attivita' antiproliferativa
ES2859460T3 (es) Proceso de fabricación de 1-(arilmetil)quinazolina-2,4(1H, 3H)–diona
Moustafa et al. Design, synthesis, biological and molecular docking studies of some o-hydroxycyanopyridine derivatives
Zhai et al. Discovery of novel tricyclic 5 H-Pyridazino [4, 5-b] indoles as potent antitumor agents: Design, synthesis and biological evaluation
CN114728963B (zh) 新型三唑吡啶衍生物和包括其的药物组合物
WO2018151633A1 (ru) Способы получения производных 4-(((нафталин-2-ил)алкил)амино)хинозалин-6-карбонитрилов
JP2025533275A (ja) Ｙａｐ－ｔｅａｄ相互作用を阻害するための新規なヘテロ二環式化合物及びそれを含む薬学的組成物
HK40018820B (en) Egfr inhibitor, and preparation and application thereof
Zheng et al. Design, synthesis, crystal structure and antitumor activity of a new ethyl 3-(quinazolin-4-ylamino)-1H-pyrrole-2-carboxylate derivative
Patila et al. Synthesis and antimicrobial screening of some new N 3-substituted derivatives of quinazolin-4 (3H)-one

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130404